Cargando…

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

The prognosis for patients with glioblastoma is grim. Ex vivo expanded tumor-associated antigen (TAA)-reactive T-cells from patients with glioma may represent a viable source for anticancer-directed cellular therapies. Immunohistochemistry was used to test the survivin (n = 40 samples) and NY-ESO-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhenjiang, Poiret, Thomas, Persson, Oscar, Meng, Qingda, Rane, Lalit, Bartek, Jiri, Karbach, Julia, Altmannsberger, Hans-Michael, Illies, Christopher, Luo, Xiaohua, Harvey-Peredo, Inti, Jäger, Elke, Dodoo, Ernest, Maeurer, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799356/ https://www.ncbi.nlm.nih.gov/pubmed/29058035 http://dx.doi.org/10.1007/s00262-017-2066-z

Ejemplares similares

Expression of TAAs in glioblastoma and expansion of anti-TAA -reactive T cells
por: Dodoo, Ernest, et al.
Publicado: (2014)

Cytokine Networks and Survivin Peptide-Specific Cellular Immune Responses Predict Improved Survival in Patients With Glioblastoma Multiforme
por: Zhenjiang, Liu, et al.
Publicado: (2018)

Rapid expansion of TILs from patients with glioma and recognition of autologous tumor
por: Zhenjiang, Liu, et al.
Publicado: (2014)

Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis
por: Zhenjiang, Liu, et al.
Publicado: (2017)

IL-2, IL-15 and IL-21 expand T cells for targeted adoptive therapy
por: Liu, Zhenjiang, et al.
Publicado: (2015)

Enhanced tumor-infiltrating lymphocytes (eTIL) for cellular therapy of patients with pancreatic cancer or glioblastoma
por: Meng, Qingda, et al.
Publicado: (2015)

Epstein–Barr virus- and cytomegalovirus-specific immune response in patients with brain cancer
por: Liu, Zhenjiang, et al.
Publicado: (2018)

Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

Correction: Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

A fast assay to gauge for TAA-reactive T cells in PBMCS from patients with pancreatic cancer
por: Rangelova, Elena B, et al.
Publicado: (2014)

Generation of tumor-infiltrating lymphocytes from pancreatic cancer lesions for cellular therapy
por: Meng, Qingda, et al.
Publicado: (2014)

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4(+)T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
por: Jäger, Elke, et al.
Publicado: (2000)

Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer
por: Karbach, Julia, et al.
Publicado: (2023)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes
por: Jäger, Elke, et al.
Publicado: (1998)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumors
por: Meng, Qingda, et al.
Publicado: (2018)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

T-Cell Therapy: Options for Infectious Diseases
por: Parida, Shreemanta K., et al.
Publicado: (2015)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

NY-ESO-1 expression in DCIS: A new predictor of good prognosis
por: Coombes, R. Charles, et al.
Publicado: (2017)

Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer
por: Meng, Qingda, et al.
Publicado: (2018)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer
por: Milne, Katy, et al.
Publicado: (2008)

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability
por: Sommermeyer, Daniel, et al.
Publicado: (2013)

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma
por: Zhang, Zhen, et al.
Publicado: (2017)

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
por: Gyurdieva, Alexandra, et al.
Publicado: (2022)

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
por: Zhou, Hong, et al.
Publicado: (2023)

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012)

Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)

Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma
por: Giavina-Bianchi, Mara, et al.
Publicado: (2015)

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients
por: Camisaschi, Chiara, et al.
Publicado: (2018)

Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules
por: Bethune, Michael T., et al.
Publicado: (2018)

Prognostic impact of p53 and/or NY‐ESO‐1 autoantibody induction in patients with gastroenterological cancers
por: Hoshino, Isamu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_it80musfg1tcfbqa2onnt9bial